Capital International Investors Autolus Therapeutics PLC Transaction History

Capital International Investors

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2021 Aug 16, 2021	SELL	$4.78 - $7.96 $10.9 Million - $18.1 Million	-2,272,728 Closed	0 $0
Q1 2021 May 14, 2021	BUY	$5.49 - $9.36 $5.76 Million - $9.83 Million	1,050,040 Added 85.88%	2,272,728 $13 Million
Q1 2020 May 15, 2020	BUY	$4.2 - $13.0 $2.3 Million - $7.12 Million	547,800 Added 81.17%	1,222,688 $7.32 Million
Q3 2019 Nov 14, 2019	BUY	$9.79 - $16.72 $1.82 Million - $3.11 Million	186,000 Added 38.05%	674,888 $8.38 Million
Q3 2018 Nov 14, 2018	BUY	$20.86 - $33.33 $10.2 Million - $16.3 Million	488,888 New	488,888 $14.7 Million

104

163M

2.8K

13.4K

Ticker AUTL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 90,909,800
Market Cap $272M
Description
Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which...

Get notified when there are updates to the investment portfolio of Capital International Investors, based on Form 13F filings with the SEC.

Stay updated on Capital International Investors with notifications on news.